Midi Health’s NAD+ offer is a prescription nasal spray, not an injection kit. It belongs in a broader comparison because some readers searching for injections are really looking for a manageable way to discuss energy or concentration changes in midlife. The route should be clear before anyone compares the price with a vial or IV appointment.
On September 19, 2026, Midi’s product page advertised $165 for a 30-day, 15 mL supply. We reviewed the product page, Custom Rx information, and linked safety monograph. We did not attend a consultation or try the spray. This review also identifies unclear wording in the safety material that deserves a direct clinical answer.
Midi provides a nasal alternative within a midlife-care setting. Separate medication cost from visit cost, and resolve the linked monograph’s unclear eligibility and storage wording with the clinician and pharmacy.
What is being prescribed?
The official product page describes a prescription NAD+ spray evaluated by a Midi clinician and shipped to the patient. The linked monograph identifies a compounded formulation. An interest in avoiding needles may make the format relevant, but it does not establish equal effects, absorption, or suitability compared with another route.
Use our injection-versus-nasal-spray guide before asking the clinician to compare options. A nasal product should be used only according to its own prescription and pharmacy label. Its bottle volume cannot be converted into an injection plan, and injection instructions should never be borrowed for this preparation.
Separate the medication price from the visit
The advertised $165 covers the stated 30-day, 15 mL supply. Midi’s Custom Rx information says its compounded Custom Rx treatments are cash-pay and require a visit. Do not assume that insurance acceptance for some Midi medical care means the NAD+ spray or all related charges are covered.
Ask for the consultation cost under your actual insurance or self-pay arrangement, the medication total, shipping, and follow-up charges. Also ask how and when refills are ordered. The NAD+ cost guide helps keep these components visible instead of treating the product price as the cost of an entire care relationship.
A midlife consultation should consider the whole concern
Midi’s service context may appeal to someone who wants to discuss symptoms alongside other midlife health issues. The useful part of that visit is the assessment, not an assumption that NAD+ explains every change in energy or memory. Describe when symptoms began, how they affect daily life, and what else has changed.
Our NAD+ after 50 guide offers a way to prepare that history. Ask the clinician which alternative explanations and treatments deserve consideration. If the visit results in a different recommendation or no NAD+ prescription, that can still be a useful clinical outcome rather than a failed shopping experience.
Clarify the safety monograph before use
The linked safety monograph contains unclear wording: a pregnancy/breastfeeding section begins with a general exclusion of women, despite the product’s midlife positioning. Its storage sentence also combines room-temperature and refrigerator language without a clear single instruction. We cannot safely resolve either inconsistency on the provider’s behalf.
Ask the clinician and dispensing pharmacist to explain eligibility and provide unambiguous written handling directions for your prescription before using it. This is a request to clarify the published material, not a conclusion that every woman is ineligible. Keep the pharmacy label and the clinician’s explanation together, especially if they differ from the general webpage.
Do not treat an advertised timeline as a guarantee
The product page describes customer-reported alertness and mental-clarity changes over short time periods. Those statements are provider marketing, not a controlled study establishing how the spray will work for you. We have not verified a trial of this exact formulation that demonstrates the advertised patient outcomes.
The evidence review explains the gap between NAD biology and clinical benefits. Compounded NAD+ is not FDA-approved. Ask what outcome would be meaningful to track, how long a reassessment interval is appropriate, and which symptoms should prompt a separate evaluation instead of continuing to wait for a marketed effect.
Make the follow-up arrangement concrete
Midi’s product page describes booking a follow-up visit to discuss progress. Before enrollment, ask who to contact between appointments and whether there is a separate charge for that conversation. A routine billing inquiry, a question about the spray device, and a concern about symptoms may require different people.
If you already use other nasal medicines or have nasal sensitivities, raise those details with the clinician rather than selecting the spray purely to avoid needles. The monograph itself advises caution around nasal conditions. Request instructions matched to the actual bottle and device, and ask the pharmacist to demonstrate or explain anything that remains unclear.
Compare Midi with the right alternatives
The Shed review covers a service advertising several routes under one NAD+ heading. Our CoreAge Rx review covers the featured commercial partner’s online offer, including its injection and nasal options. Neither comparison establishes that the different preparations are clinically interchangeable.
If you specifically want supervised administration, explore the Restore review and the local directory instead. The strongest reason to choose a care setting is that it supports an appropriate assessment and an understandable plan. A needle-free format may suit a preference, but convenience alone does not settle the treatment decision.
Follow the source
References & further reading
- Midi Health — NAD+ nasal spray
Nasal product offer checked September 19, 2026. This is not an injection-kit offer; the advertised price is for the stated supply.
- Midi — Custom Rx visits and payment
Provider FAQ identifies Custom Rx as cash-pay and visit-dependent; do not infer NAD+ coverage from general insurance participation.
- Midi — NAD+ nasal-spray monograph
Safety text reviewed September 19, 2026 contains unclear eligibility and storage wording. The review flags it for clinician and pharmacist clarification.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- NIH — niacin health professional fact sheet
Biology and nutritional context, not evidence for a finished injectable medicine.
- HHS — licensing across state lines
Licensing pathways vary by state and profession; confirm your clinician can treat you where you are located.